<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01526408</url>
  </required_header>
  <id_info>
    <org_study_id>HRI-003</org_study_id>
    <secondary_id>Meniere's Disease</secondary_id>
    <nct_id>NCT01526408</nct_id>
  </id_info>
  <brief_title>Famvir for Treatment of Hearing in Unilateral Meniere's Disease</brief_title>
  <acronym>Famvir</acronym>
  <official_title>Treatment of Hearing Fluctuation in Unilateral Meniere's Disease: A Randomized, Placebo-controlled Clinical Trial of Famciclovir</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>House Research Institute</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>House Clinic, Inc.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>House Research Institute</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The specific aim of this study is to determine the efficacy of treatment with famciclovir in&#xD;
      unilateral Meniere's Disease patients, specifically whether hearing can be improved. The&#xD;
      investigators will determine the percentage of unilateral Meniere's Disease patients&#xD;
      experiencing an absence of hearing fluctuation after 3 months of treatment with famciclovir&#xD;
      as compared to the placebo arm.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    HRI no longer conducting research.&#xD;
  </why_stopped>
  <start_date>December 2011</start_date>
  <completion_date type="Actual">March 2015</completion_date>
  <primary_completion_date type="Actual">January 2015</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Pure-tone Threshold Change</measure>
    <time_frame>3 months</time_frame>
    <description>Change in hearing from baseline to after 3 months of treatment</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Tinnitus and/or Dizziness Handicap Change</measure>
    <time_frame>3 months</time_frame>
    <description>Change in tinnitus and/or dizziness from baseline to after 3 months of treatment</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">11</enrollment>
  <condition>Meniere's Disease</condition>
  <arm_group>
    <arm_group_label>Placebo Arm</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Treatment with 3 months of placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Active Arm</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Treatment with 3 months of active drug</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Famciclovir</intervention_name>
    <description>Patients will be instructed to take 6 250mg pills orally for the first 7 days (Week 1: 2 pills every 8 hours or three times per day) at home. Patients will take a maintenance dose of one 250 mg pill twice a day for 77 days (11 weeks, total 3 months on drug).</description>
    <arm_group_label>Active Arm</arm_group_label>
    <other_name>Famvir</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Patients will be instructed to take 6 250mg pills orally for the first 7 days (Week 1: 2 pills every 8 hours or three times per day) at home. Patients will take a maintenance dose of one 250 mg pill twice a day for 77 days (11 weeks, total 3 months).</description>
    <arm_group_label>Placebo Arm</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Unilateral Meniere's Disease&#xD;
&#xD;
          -  2 vertigo episodes of at least 20 minutes&#xD;
&#xD;
          -  Fluctuating hearing by subjective history and/or audiometric documentation.&#xD;
             Audiometric documentation is defined as affected ear pure-tone average change from an&#xD;
             audiogram at Time 1 to Time 2 (less than one year apart) of greater than 15 dB.&#xD;
&#xD;
          -  Less than 45 dB 4-frequency pure-tone average in the affected ear&#xD;
&#xD;
          -  Tinnitus and/or aural fullness&#xD;
&#xD;
          -  Willing to undergo the clinical trial procedures&#xD;
&#xD;
          -  Signed informed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Acute or chronic middle ear disease in either ear&#xD;
&#xD;
          -  Only hearing ear&#xD;
&#xD;
          -  4-frequency pure-tone average &gt; 45 dB in either ear&#xD;
&#xD;
          -  Known allergy to famciclovir or any of the ingredients in the formulation&#xD;
&#xD;
          -  Taking oral steroids or receiving IT steroids at time of enrollment. If the subject&#xD;
             has been on oral steroids/IT steroids, 3 months must elapse from last dose to start of&#xD;
             treatment in the study&#xD;
&#xD;
          -  Must not have had previous inner ear surgery&#xD;
&#xD;
          -  History of immunodeficiency diseases such as HIV&#xD;
&#xD;
          -  History of renal insufficiency or other kidney diseases&#xD;
&#xD;
          -  A female of child-bearing potential who is pregnant&#xD;
&#xD;
          -  History of noncompliance to medical regimens&#xD;
&#xD;
          -  Unwilling to or unable to comply with the protocol, including scheduling study&#xD;
             evaluations&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>90 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jennifer Derebery, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>House Research Institute</affiliation>
  </overall_official>
  <removed_countries>
    <country>United States</country>
  </removed_countries>
  <verification_date>March 2021</verification_date>
  <study_first_submitted>January 31, 2012</study_first_submitted>
  <study_first_submitted_qc>February 2, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 3, 2012</study_first_posted>
  <results_first_submitted>March 24, 2021</results_first_submitted>
  <results_first_submitted_qc>March 24, 2021</results_first_submitted_qc>
  <results_first_posted type="Actual">April 19, 2021</results_first_posted>
  <last_update_submitted>March 24, 2021</last_update_submitted>
  <last_update_submitted_qc>March 24, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">April 19, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>House Research Institute</investigator_affiliation>
    <investigator_full_name>M. Jennifer Derebery</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>Meniere's Disease</keyword>
  <keyword>Vertigo</keyword>
  <keyword>Hearing loss</keyword>
  <keyword>Tinnitus</keyword>
  <keyword>Anti-viral</keyword>
  <keyword>Famciclovir</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Meniere Disease</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Famciclovir</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Placebo Arm</title>
          <description>Treatment with 3 months of placebo&#xD;
Placebo: Patients will be instructed to take 6 250mg pills orally for the first 7 days (Week 1: 2 pills every 8 hours or three times per day) at home. Patients will take a maintenance dose of one 250 mg pill twice a day for 77 days (11 weeks, total 3 months).</description>
        </group>
        <group group_id="P2">
          <title>Active Arm</title>
          <description>Treatment with 3 months of active drug&#xD;
Famciclovir: Patients will be instructed to take 6 250mg pills orally for the first 7 days (Week 1: 2 pills every 8 hours or three times per day) at home. Patients will take a maintenance dose of one 250 mg pill twice a day for 77 days (11 weeks, total 3 months on drug).</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="0">early termination of study and sponsor organization closed</participants>
                <participants group_id="P2" count="0">early termination of study and sponsor organization closed</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0">early termination of study and sponsor organization closed</participants>
                <participants group_id="P2" count="0">early termination of study and sponsor organization closed</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>early termination of study and sponsor organization closed</population>
      <group_list>
        <group group_id="B1">
          <title>Placebo Arm</title>
          <description>Treatment with 3 months of placebo&#xD;
Placebo: Patients will be instructed to take 6 250mg pills orally for the first 7 days (Week 1: 2 pills every 8 hours or three times per day) at home. Patients will take a maintenance dose of one 250 mg pill twice a day for 77 days (11 weeks, total 3 months).</description>
        </group>
        <group group_id="B2">
          <title>Active Arm</title>
          <description>Treatment with 3 months of active drug&#xD;
Famciclovir: Patients will be instructed to take 6 250mg pills orally for the first 7 days (Week 1: 2 pills every 8 hours or three times per day) at home. Patients will take a maintenance dose of one 250 mg pill twice a day for 77 days (11 weeks, total 3 months on drug).</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="0"/>
            <count group_id="B2" value="0"/>
            <count group_id="B3" value="0"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                </category>
                <category>
                  <title>Male</title>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race and Ethnicity Not Collected</title>
          <population>Race and Ethnicity were not collected from any participant.</population>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <class_list>
            <class>
              <title>United States</title>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Pure-tone Threshold Change</title>
        <description>Change in hearing from baseline to after 3 months of treatment</description>
        <time_frame>3 months</time_frame>
        <population>early termination of study and sponsor organization closed</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo Arm</title>
            <description>Treatment with 3 months of placebo&#xD;
Placebo: Patients will be instructed to take 6 250mg pills orally for the first 7 days (Week 1: 2 pills every 8 hours or three times per day) at home. Patients will take a maintenance dose of one 250 mg pill twice a day for 77 days (11 weeks, total 3 months).</description>
          </group>
          <group group_id="O2">
            <title>Active Arm</title>
            <description>Treatment with 3 months of active drug&#xD;
Famciclovir: Patients will be instructed to take 6 250mg pills orally for the first 7 days (Week 1: 2 pills every 8 hours or three times per day) at home. Patients will take a maintenance dose of one 250 mg pill twice a day for 77 days (11 weeks, total 3 months on drug).</description>
          </group>
        </group_list>
        <measure>
          <title>Pure-tone Threshold Change</title>
          <description>Change in hearing from baseline to after 3 months of treatment</description>
          <population>early termination of study and sponsor organization closed</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Tinnitus and/or Dizziness Handicap Change</title>
        <description>Change in tinnitus and/or dizziness from baseline to after 3 months of treatment</description>
        <time_frame>3 months</time_frame>
        <population>early termination of study and sponsor organization closed</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo Arm</title>
            <description>Treatment with 3 months of placebo&#xD;
Placebo: Patients will be instructed to take 6 250mg pills orally for the first 7 days (Week 1: 2 pills every 8 hours or three times per day) at home. Patients will take a maintenance dose of one 250 mg pill twice a day for 77 days (11 weeks, total 3 months).</description>
          </group>
          <group group_id="O2">
            <title>Active Arm</title>
            <description>Treatment with 3 months of active drug&#xD;
Famciclovir: Patients will be instructed to take 6 250mg pills orally for the first 7 days (Week 1: 2 pills every 8 hours or three times per day) at home. Patients will take a maintenance dose of one 250 mg pill twice a day for 77 days (11 weeks, total 3 months on drug).</description>
          </group>
        </group_list>
        <measure>
          <title>Tinnitus and/or Dizziness Handicap Change</title>
          <description>Change in tinnitus and/or dizziness from baseline to after 3 months of treatment</description>
          <population>early termination of study and sponsor organization closed</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>early termination of study and sponsor organization closed</time_frame>
      <desc>early termination of study and sponsor organization closed</desc>
      <group_list>
        <group group_id="E1">
          <title>Placebo Arm</title>
          <description>Treatment with 3 months of placebo&#xD;
Placebo: Patients will be instructed to take 6 250mg pills orally for the first 7 days (Week 1: 2 pills every 8 hours or three times per day) at home. Patients will take a maintenance dose of one 250 mg pill twice a day for 77 days (11 weeks, total 3 months).</description>
        </group>
        <group group_id="E2">
          <title>Active Arm</title>
          <description>Treatment with 3 months of active drug&#xD;
Famciclovir: Patients will be instructed to take 6 250mg pills orally for the first 7 days (Week 1: 2 pills every 8 hours or three times per day) at home. Patients will take a maintenance dose of one 250 mg pill twice a day for 77 days (11 weeks, total 3 months on drug).</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Mahta Marefat</name_or_title>
      <organization>House Institute Foundation</organization>
      <phone>(213) 770-1808</phone>
      <email>mmarefat@hifla.org</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

